title: [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].
abstract: RTOG and EORTC randomised phase III trials investigated combination of radiation therapy and hormonal treatment in locally advanced prostate cancer T2c-T4 N0-1 M0 (UICC 2002). Complete androgen blockade initiated 2 months prior to starting radiotherapy and stopped at the completion of radiotherapy vs radiation therapy alone, increased overall survival in patients with Gleason score 2-6. Adjuvant androgen suppression started at the end of the radiotherapy and continued indefinitely improved significantly overall survival of patients Gleason score 8 to 10. Complete androgen blockade in two months before and two months during radiation followed by 24 additional months of LHRH analogue alone improved overall survival of patients Gleason score 8-10 with respect to CAB alone. EORTC trial 22861 has shown that androgen suppression with LHRH analogue given during and for 3 years after external irradiation improved overall survival whatever the Gleason score. The role of hormonal treatment is currently assessed in localized prostate cancer (T1-2 N0) with poor prognostic factors: Gleason score 8-10, PSA>20 ng/ml.
authors.affiliation: Département de cancérologie-hématologie, CHU de Grenoble, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Bolla
authors.forename: Philippe
authors.initials: P
authors.lastname: Maingon
authors.forename: Philippe
authors.initials: P
authors.lastname: Fourneret
authors.forename: Xavier
authors.initials: X
authors.lastname: Artignan
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Descotes
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D013534:Survival; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists